Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.41 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL391441 | 0.98 | PARP1 (0.44) | PARP1PDPK1JAK2RPS6KA3MELK | |
| SCHEMBL21243890 | 0.75 | PARP1 (0.40) | PARP1PDPK1RECQLTDP1RAB9A | |
| SCHEMBL4419238 | 0.74 | TNF (0.39) | PDPK1CYP2A6MAPTRAB9A | |
| SCHEMBL8180483 | 0.74 | CYP2A6 (0.34) | CYP2A6PIM1 | |
| SCHEMBL3840439 | 0.70 | CYP1A2 (0.36) | PARP1PDPK1CYP2A6 | |
| SCHEMBL6650051 | 0.69 | PDPK1 (0.44) | PARP1PDPK1CYP2A6DAOMAPT | |
| SCHEMBL396627 | 0.67 | — | — | |
| SCHEMBL793638 | 0.67 | CYP2A6 (0.46) | PARP1PDPK1CYP2A6DAOPIM1 | |
| SCHEMBL16596109 | 0.67 | EGFR (0.35) | PARP1CYP2A6 | |
| SCHEMBL9550048 | 0.67 | ALDH1A1 (0.46) | PARP1PDPK1JAK2RPS6KA3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029610-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | claimed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | claimed |
| US-12545700-B2 | Excitonic quantum computing via aggregate-aggregate coupling | BOISE STATE UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-12479998-B2 | Dyes in dye aggregate systems—engineering J, K, and dye packing | BOISE STATE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12292668-B2 | Molecular aggregate for optically-pumped nonreciprocal exciton devices | BOISE STATE UNIVERSITY (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250092054-A1 | FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS | FMC CORPORATION | 2025-03-20 | — | — | US | disclosed |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12173027-B2 | Excitonic quantum computing mediated by chromophore-embedded 1-, 2-, and 3-dimensional DNA scaffolds | BOISE STATE UNIVERSITY (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024238871-A1 | ARYL SULFONAMIDE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
| CN-1093856-C | Substituted sulfonic acid N- [ (aminoiminomethyl) phenylalkyl ] -azacyclic amide compounds | AVENTIS PHARM PROD INC (US) | 2002-11-06 | — | — | CN | disclosed |
| EP-0894088-A4 | SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6034093-A | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0894088-A1 | SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998024784-A1 | SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0271273-A2 | Thieno-and furopyridine sulfonamides | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4731368-A | Thienopyridine sulfonamides and their ophthalmological formulation | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092054-A1 | FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS | PRF1, ACHE, C5 | PARP1 2920/4885PDPK1 225/4885JAK2 2020/4885 |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | PTP4A3, PTPRO, PTPRC | PARP1 1151/4885PDPK1 221/4885JAK2 103/4885 |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | PARP1 1320/4885PDPK1 2642/4885JAK2 1783/4885 |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | PTP4A3, PTPRC, PTPRF | PARP1 1313/4885PDPK1 147/4885JAK2 86/4885 |
| US-12545700-B2 | Excitonic quantum computing via aggregate-aggregate coupling | ELAVL1, ELAVL3, NCAPH | PARP1 416/4885PDPK1 4217/4885JAK2 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.